Healthcare Industry News: regenerative tissue matrix
News Release - February 4, 2013
Graftjacket(R) Regenerative Tissue Matrix Receives Medicare Reimbursement in Ten Northwestern StatesApproximately 3.7 Million People Gain Access to Effective Treatment Option for Diabetic Foot Ulcers
SAN ANTONIO--(Healthcare Sales & Marketing Network)--Kinetic Concepts, Inc. today announced that Medicare and Medicare Advantage Health plan beneficiaries living in ten Midwestern states now have access to the KCI Graftjacket® regenerative tissue matrix (RTM) for the treatment of diabetic foot ulcers (DFUs). DFUs remain one of the most debilitating complications from diabetes, with approximately 85 percent of all non-traumatic amputations preceded by a non-healing foot ulcer.1 Graftjacket® RTM is an acellular dermal allograft marketed and sold by KCI for the treatment of wounds such as DFUs.
Graftjacket® RTM was recently approved for coverage and reimbursement by Noridian Administrative Services, a Medicare Administrative Contractor (MAC). This new Local Coverage Determination (LCD) policy gives more than 3.7 million Medicare beneficiaries in ten states of current Noridian jurisdiction – Arizona, Alaska, Idaho, Montana, North Dakota, South Dakota, Oregon, Utah, Washington and Wyoming – access to a proven treatment option for DFUs.
“KCI is dedicated to providing a continuum of care for patients suffering from chronic wounds and we are pleased this new coverage by Noridian gives DFU patients in this region of the United States access to Graftjacket® RTM,” said Jim Cunniff, senior vice president, Americas, KCI. “Graftjacket® RTM and our negative pressure technology product portfolio offer clinicians cost-effective treatment options when dealing with debilitating conditions.”
With this coverage, Graftjacket® RTM (for DFUs) is now covered in 49 states in the outpatient setting. It is also used for more severe wounds in the surgical suite (inpatient setting).
Graftjacket® RTM is indicated for the repair or replacement of damaged or inadequate integumental tissue, such as diabetic ulcers, venous leg ulcers, pressure ulcers or for other homologous uses of human integument. Proprietary processing allows the body to accept Graftjacket® RTM and helps reduce the potential for a rejection response. Graftjacket® RTM provides immediate coverage to the wound and is readily repopulated with the patient's own cells and revascularized by the body. Ultimately, Graftjacket® RTM acts as a scaffold that allows the body to convert the matrix to functional host tissue in wound repair.
For more information about KCI and Graftjacket® RTM, please visit www.kci1.com and graftjacketbykci.com.
Kinetic Concepts, Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 25 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively affecting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.
1. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care. 1998 Dec;21(12):2161-77.
Source: Kinetic Concepts
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.